Therapeutic challenges posed by bacterial bioterrorism threats

Current Opinion in Microbiology

Volumn 5, Issue 5, 2002, Pages 489-495

  Gilligan, Peter H ^a  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CEPHALOSPORINASE; CHLORAMPHENICOL; CHLORAMPHENICOL ACETYLTRANSFERASE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; NITROCEFIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN;

AGAR GEL DIFFUSION; ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; BRUCELLA; BRUCELLOSIS; BURKHOLDERIA PSEUDOMALLEI; CLINICAL TRIAL; FRANCISELLA TULARENSIS; HORSE DISEASE; HUMAN; MELIOIDOSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLAGUE; POLYMERASE CHAIN REACTION; REVIEW; SEROLOGY; TULAREMIA; YERSINIA PESTIS;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS); BRUCELLA; BURKHOLDERIA; BURKHOLDERIA PSEUDOMALLEI; EQUUS CABALLUS; FRANCISELLA TULARENSIS; YERSINIA; YERSINIA PESTIS;

EID: 0036790016     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1369-5274(02)00359-4     Document Type: Review

References (59)

1. Centers for Disease Control: Biological and chemical terrorism: strategic plan for preparedness and response. MMWR Weekly Rep 2000, 49RR-4:1-26.
2. Jernigan J, Stephens D, Ashford D, Omenaca C, Topiel M, Galbraith M, Tapper M, Fisk T, Papovi T, Meyer R et al.: Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001, 7:933-944.
3. Inglesby T, O'Toole T, Henderson D, Barlett J, Ascher M, Eitzen E, Friedlander A, Gerberding J, Hauer J, Hughes J et al.: Anthrax as a biological weapon, 2002. J Am Med Assoc 2002, 287:2236-2252.
4. Centers for Disease Control. Update: Cutaneous anthrax in a laboratory worker - Texas, 2002. MMWR Weekly Rep 2002, 51:482.
5. Centers for Disease Control: Update: Adverse events associated with anthrax prophylaxis among postal employees - New Jersey, New York City, and the District of Columbia metropolitan area, 2001. MMWR Weekly Rep 2001, 50:1051-1053.
6. Mohammed M, Marston C, Popovic T, Weyant R, Tenover F: Antimicrobial susceptibility of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and E-test agar gradient diffusion methods. J Clin Microbiol 2002, 40:1902-1907.
7. NCCLS: Performance standards for antimicrobial susceptibility testing; twelfth informational supplement M100-S12. NCCLS Wayne PA 2002, 22:7-122.
8. Bradarić N, Punda-Polić V: Cutaneous anthrax due to penicillin-resistant Bacillus anthracis transmitted by an insect bite. Lancet 1992, 340:306-307.
9. Lalitha M, Thomas M: Penicillin resistance in Bacillus anthracis. Lancet 1997, 349:1522.
10. Gilbert D, Moellering R Jr, Sande M: Sanford Guide to Antimicrobial Therapy 2002, edn. 32. Hyde Park, VT: Antimicrobial Therapy, Inc; 2002.
11. Mandell G, Bennett J, Dolin R: Principles and Practice of Infectious Diseases, edn 5. Philadelphia: Churchill Livingstone; 2000.
12. Cavallo J, Ramisse F, Girardet M, Vaissaire J, Mock M, Hernandez E: Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000. Antimicrob Agent Chemother 2002, 46:2307-2309.
13. Bell D, Kozarsky P, Stephens D: Clinical issues in the prophylaxis, diagnosis and treatment of anthrax. Emerg Infect Dis 2002, 8:222-225.
14. Choe C, Bouhaouala S, Brook I, Elliott T, Knudson G: In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis Sterne. Antimicrob Agents Chemother 2000, 44:1766.
15. Vogler A, Busch J, Percy-Fine S, Tipton-Hunton C, Smith K, Keim P: Molecular analysis of rifampin resistance in Bacillus anthracis and Bacillus cereus. Antimicrob Agents Chemother 2002, 46:511-513.
16. Stepanov AV, Marinin LI, Pomerantsev AP, Staritsin NA: Development of novel vaccines against anthrax in man. J Biotechnol 1996, 44:155-160.
17. Alibek K, Handleman S: Biohazard. New York, NY: Random House, 1999.
18. Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, Shelokov A, Yampolskaya O: The Sverdolovsk anthrax outbreak of 1979. Science 1994, 266:1202-1208.
19. Inglesby T, Dennis D, Henderson D, Barlett J, Ascher M, Eitzen E, Fine A, Friedlander A, Hauer J, Koerner J et al.: Plague as a biological weapon. J Am Med Assoc 2000, 283:2281-2290.
20. Frean JA, Arntzen L, Capper T, Bryskier A, Klugman KP: In vitro activities of 14 antibiotics against 100 isolates of Yersinis pestis from a Southern African plague focus. Antimicrob Agents Chemother 1996, 40:2646-2647.
21. Wong J, Barash J, Sandfort R, Janda J: Susceptibilities of Yersinina pestis strains to 12 antimicrobial agents. Antimicrob Agents Chemother 2000, 44:1995-1996.
22. Smith M, Vinh D, Hoa N, Wain J, Thung D, White N: In vitro antimicrobial susceptibilities of strains of Yersinia pestis. Antimicrob Agents Chemother 1995, 39:2153-2154.
23. Boisier P, Rahalison L, Rasolomaharo M, Ratsitorahina M, Mahafaly M, Razafimahefa M, Duplantier J, Ratsifasoamanana L, Chanteau S: Epidemiologic features of four successive annual outbreaks of bubonic plague in Mahajanga, Madagascar. Emerg Infect Dis 2002, 8:311-316.
24. Byrne W, Welkos S, Pitt M, Davis K, Brueckner R, Ezzell J, Nelson G, Vaccaro J, Battersby L, Friedlander A: Antibiotic treatment of experimental pneumonic plague in mice. Antimicrob Agents Chemother 1998, 42:675-681.
25. Galimand M, Guiyoule A, Gerbaud G, Rasoamanana B, Chanteau S, Carniel E, Courvalin P: Multi-drug resistance in Yersinia pestis mediated by a transferable plasmid. N Engl J Med 1997, 337:677-680.
26. Guiyoule A, Gerbaud G, Buchrieser C, Galimand M, Rahalison L, Chanteau S, Courvalin P, Carniel E: Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis. Emerg Infect Dis 2001, 7:43-48.
27. Lindler L, Fan W, Jahan N: Detection of ciprofloxacin-resistant Yersinia pestis by fluorogenic PCR using the LightCycler. J Clin Microbiol 2001, 39:3649-3655.
28. Dennis D, Inglesby T, Henderson D, Bartlett J, Ascher M, Eitzen E, Fine A, Friedlander A, Hauer J, Layton M et al.: Tularemia as a biological weapon. J Am Med Assoc 2001, 285:2763-2773.
29. Shapiro D, Schwartz D: Exposure of laboratory workers to Francisella tularensis despite a bioterrorism procedure. J Clin Microbiol 2002, 40:2278-2281.
30. Clarridge J, Raich T, Sjösted A, Sandstrom G, Darouiche R, Shawar R, Geroghiou P, Osting C, Vo L: Characterization to two unusual clinically significant Francisella strains. J Clin Microbiol 1996, 46:1995-2003.
31. Cross T, Jacobs R: Tularemia: treatment failures with outpatient use of ceftriaxone. Clin Infect Dis 1993, 17:976-980.
32. Maurin M, Mersali NF, Raoult D: Bactericidal activities of antibiotics against intracellular Francisella tularensis. Antimicrob Agents Chemother 2000, 44:3428-3431.
33. Ikäheimo I, Syrjälä H, Karhukorpi J, Schildt R, Koskela M: In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J Antimicrob Chemother 2000, 46:287-290.
34. Limaye A, Hooper C: Treatment of tularemia with fluoroquinolones: Two cases and review. Clin Infect Dis 1999, 29:922-924.
35. Pérez-Castrillión J, Bachiller-Luque P, Martin-Luquero M, Mena-Martin F, Herreros V: Tularemia epidemic in northwestern Spain: clinical description and therapeutic response. Clin Infect Dis 2001, 33:573-576.
36. Johansson A, Berglund L, Gothefors L, Sjöstedt A, Tärnvik A: Ciprofloxacin for treatment of tularemia in children. Pediatr Infect Dis J 2000, 19:449-453.
37. Johansson A, Berglund L, Gothefors L, Sjöstedt A, Tärnvik A: Ciprofloxacin for the treatment of tularemia. Clin Infect Dis 2001, 33:267-268.
38. Chocarro A, Gonzalez A: Treatment of tuleremia with ciprofloxacin. Clin Infect Dis 2000, 31:623.
39. Feldman K, Enscore R, Lathrop S, Matyas B, McGuill M, Schrieffer M, Stiles-Enos D, Dennis D, Petersen L, Hayes E: An outbreak of primary pneumonic tularemia on Martha's Vineyard. New Engl J Med 2001, 345:1601-1606.
40. Johansson A, Berglund L, Eriksson U, Goransson I, Wollin R, Forsman M, Tarnvik A, Sjostedt A: Comparative analysis of PCR culture for diagnosis of ulceroglandular tularemia. J Clin Microb 2000, 38:22-26.
41. Centers for Disease Control: Laboratory-acquired human glanders - Maryland, May 2000. MMWR Weekly Rept 2000, 49:532-535.
42. Simpson A, Suputtamongkol Y, Smith M, Angus B, Rajanuwong A, Wuthiekanun V, Howe P, Walsh A, Chaowagul W, White N: Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin Infect Dis 1999, 29:381-387.
43. Jenney A, Lum G, Fisher D, Currie B: Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int J Antimicrob Agents 2001, 17:109-113.
44. Radu S, Ling O, Srimontree S, Lulitanond A, Hin W, Yuherman, Lihan S, Rusul G, Mutalib A: Characterization of Burholdeia pseudomallei isolated in Thailand and Malaysia. Diagn Microb Infect Dis 2000, 38:141-145.
45. Smith M, Wuthiekanun V, Walsh A, White N: Susceptibility of Pseudomonas pseudomalli to some newer β-lactam antibiotics and antibiotic combinations using time-kill studies. J Antimicrob Chemother 1994, 33:145-149.
46. Kenny D, Russell P, Rogers D, Eley S, Titball R: In vitro susceptibilities of Burkholderia mallei in comparison to those of other pathogenic Burkholderia spp. Antimicrob Agents Chemother 1999, 43:2773-2775.
47. Lumbiganon P, Tattawasatra U, Chetchotisakd P, Wongratanacheewin S, Thinkhamrop B: Comparison between the antimicrobial susceptibility of Burkholderia pseudomallei to trimethoprim-sulfamethoxazole by standard disk diffusion method and by minimal inhibitory concentration determination. J Med Assoc Thai 2000, 83:856-860.
48. Seymour-Murray J, Norton R, Ashurst-Smith C: Comparative in vitro susceptibility of Burkholderia pseudomallei to cefpirome, ceftazidime and cefepime. Pathology 1997, 29:329-330.
49. Gilligan PH: Microbiology of airway disease in patients with cystic fibrosis. Rev Clin Microbiol 1991, 4:35-51.
50. Heine H, England M, Waag D, Byrne W: In vitro antibiotic susceptibilities of Burkholderia mallei (causative agent of glanders) determined by broth microdilution and E-test. Antimicrob Agents Chemother 2001, 45:2119-2121.
51. Russell R, Eley S, Green M, Bell D, Kenny D, Titball R: Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders. J Antimicrob Chemother 2000, 45:813-818.
52. Young EJ: Human brucellosis. Rev Infect Dis 1983, 5:821-842.
53. Garcia-Rodriguez J, Bellido L, Fresnadillo M, Trujillano I: In vitro activities of new macrolides and rifapentine against Brucella spp. Antimicrob Agents Chemother 1993, 37:911-913.
54. Solera J, Rodriguez-Zapata M, Geijo P, Largo J, Paulino J, Saez L, Martinez-Alfaro E, Sanchez L, Septulveda M, Ruiz-Ribo M et al.: Doxcycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. Antimicrob Agents Chemother 1995, 39:2061-2067.
55. Trujillano-Martin I, Garcia-Sanchez E, Martniex I, Fresnadillo M, Garcia-Sanchez J, Garcia-Rodriguez J: In vitro activities of six new fluoroquinolones against brucella meliensis. Antimicrob Agents Chemother 1999, 43:194-195.
56. Landines R, Linares J, Loza E, Marinez-Beltran J, Martin R, Baquero F: In vitro activity of azithromycin and tetracycline against 358 clinical isolates of Brucella melitensis. Eur J Clin Microb Infect Dis 1992, 11:265-267.
57. Fiori P, Mastrandrea S, Rappelli P, Cappuccinelli P: Brucella abortus infection acquired in microbiology laboratories. J Clin Microbiol 2000, 38:2005-2006.
58. Zoon K: Vaccines, pharmaceutical products and bioterrorism: challenges for the US Food and Drug Administration. Emerg Infect Dis 1999, 5:34-36.
59. Breman J, Henderson D: Diagnosis and management of smallpox. N Engl J Med 2002, 346:1300-1308.